Genomics informs glioblastoma biology
Related Experiment Video
Updated: May 7, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
David L Schonberg1, Shideng Bao, Jeremy N Rich
1Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Abstract:
Identifying genomic alterations in cancer does not guarantee therapeutic benefit. A new study combining DNA and RNA sequencing with functional validation uncovers new genetic driver alterations in glioblastoma with potential for clinical translation.
Insights
Identifying new genetic drivers in glioblastoma is crucial for effective cancer treatment. This study combines DNA/RNA sequencing and functional validation to find novel alterations with clinical potential.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Genomic alterations in cancer do not always predict therapeutic response.
- Glioblastoma (GBM) remains a challenging brain tumor with limited treatment options.
Discussion:
- Integrating DNA and RNA sequencing provides a comprehensive view of cancer genomes.
- Functional validation is essential to confirm the clinical relevance of identified alterations.
Key Insights:
- The study identified novel genetic driver alterations in glioblastoma.
- These findings highlight the importance of multi-omic approaches for uncovering cancer mechanisms.
Outlook:
- The identified alterations hold potential for clinical translation in glioblastoma treatment.
- Further research may lead to targeted therapies based on these genetic drivers.
More Related Videos
10:58Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
Published on: February 22, 2015
05:45Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections
Published on: July 31, 2017
